Monitor for future equity award grants under the expanded plan, which could signal management's confidence or need for retention incentives. The 10.4% potential dilution is notable for a biotech with a ~$509M market cap, but is standard for a pre-commercial stage company. No immediate trading catalyst.
Price Chart
Executive Summary
Artiva Biotherapeutics held its 2026 Annual Meeting on September 8, 2026, where stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve by 5,097,095 shares and modifying the annual automatic increase calculation to include pre-funded warrant shares. The meeting also saw the re-election of Class II directors Brian Daniels and Laura Stoppel, and the ratification of KPMG as auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 5,097,095 shares.
- The amendment also modifies the annual automatic share reserve increase calculation to include shares issuable upon exercise of pre-funded warrants.
- Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. were re-elected to three-year terms.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- The total share reserve under the amended plan is 13,328,057 shares.
- As of the record date (July 20, 2026), 48,885,777 shares of common stock were outstanding.
Financial Impact
No direct financial impact. The equity plan amendment increases potential dilution by up to 5,097,095 shares (approximately 10.4% of shares outstanding as of the record date), but shares are issued only upon future award grants and vesting.
Risk Factors
- Potential dilution from future equity awards under the expanded plan.
- No financial results or guidance were provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-389308 |
| Document: artv-20260908.htm | 0001193125-26-389308 |
| Document: 0001193125-26-389308-index-headers.html | 0001193125-26-389308 |
| Document: 0001193125-26-389308-index.html | 0001193125-26-389308 |
| Document: 0001193125-26-389308.txt | 0001193125-26-389308 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access